Characteristics and Prognostic Factors of Bone Metastasis in Patients With Colorectal Cancer

被引:48
作者
Kawamura, Hidetaka [1 ]
Yamaguchi, Tatsuro [1 ,2 ]
Yano, Yuuta [1 ]
Hozumi, Takahiro [3 ]
Takaki, Yasunobu [4 ]
Matsumoto, Hiroshi [1 ]
Nakano, Daisuke [1 ]
Takahashi, Keiichi [1 ]
机构
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan
[2] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hereditary Tumor Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Orthoped, Bunkyo Ku, Tokyo, Japan
[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Radiol, Bunkyo Ku, Tokyo, Japan
关键词
Bone metastasis; Colorectal carcinoma; Prognosis; SCORING SYSTEM; SKELETAL COMPLICATIONS; SPINAL COLUMN; SURVIVAL; IBANDRONATE; DISEASE; BISPHOSPHONATES; RADIOTHERAPY; MECHANISMS;
D O I
10.1097/DCR.0000000000001071
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Because bone metastasis from colorectal cancer is rare, there are little available data regarding such cases. OBJECTIVE: The study aim was to identify the prognostic factors and characteristics associated with survival in colorectal cancer patients with bone metastasis. DESIGN: This was a retrospective study from a prospectively collected database. SETTINGS: The study took place in a multidisciplinary, high-volume tertiary cancer center in Japan. PATIENTS: Examined were records from 104 consecutive patients treated between 2004 and 2015 for bone metastasis from colorectal cancer. MAIN OUTCOME MEASURES: The primary outcome measure was overall survival. RESULTS: The spine was the most common site of bone metastasis from colorectal cancer. Right colon cancer correlated significantly with long bone metastasis (p = 0.046), whereas left colon cancer correlated significantly with spinal bone metastasis (p = 0.034). Liver metastasis was also significantly correlated with spinal bone metastasis (p = 0.036). The median interval between the primary therapy for colorectal cancer and the metachronous diagnosis of bone metastasis was 20.0 months (quartile 1 to quartile 3, 9.0-46.5 mo). The median survival time from diagnosis of bone metastasis from colorectal cancer was 5.0 months (95% CI, 4.0-9.0 mo), and the 1-year survival rate was 30.0% (95% CI, 21.1%-39.4%). Multivariate analysis revealed that = 2 extra-bone metastatic organs, hypercalcemia, and pathologic fractures were independent poor prognostic factors (p < 0.001, 0.001, and 0.033). The number of extra-bone metastatic organs correlated with prognosis. LIMITATIONS: This study was limited by its retrospective, nonrandomized design, as well as selection bias and performance at a single institute. CONCLUSIONS: The location of colorectal cancer correlates significantly with the site of bone metastasis; the prognosis of patients with bone metastasis from colorectal cancer is very poor, and the significant prognostic factors are number of extra-bone metastatic organs, hypercalcemia, and pathologic fractures. See Video Abstract at http://links.lww.com/DCR/A589.
引用
收藏
页码:673 / 678
页数:6
相关论文
共 28 条
[1]   Interleukin-6 in bone metastasis and cancer progression [J].
Ara, Tasnim ;
DeClerck, Yves A. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (07) :1223-1231
[2]   The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution [J].
Baek, Se-Jin ;
Hur, Hyuk ;
Min, Byung-Soh ;
Baik, Seung-Hyuk ;
Lee, Kang-Young ;
Kim, Nam-Kyu .
WORLD JOURNAL OF SURGERY, 2016, 40 (04) :982-986
[3]   SURVIVAL AFTER SURGERY FOR SPINAL AND EXTREMITY METASTASES - PROGNOSTICATION IN 241 PATIENTS [J].
BAUER, HCF ;
WEDIN, R .
ACTA ORTHOPAEDICA SCANDINAVICA, 1995, 66 (02) :143-146
[4]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[5]   Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer [J].
Body, JJ ;
Diel, IJ ;
Bell, R ;
Pecherstorfer, M ;
Lichinitser, MR ;
Lazarev, AF ;
Tripathy, D ;
Bergström, B .
PAIN, 2004, 111 (03) :306-312
[6]  
Buckwalter JA, 1997, AM FAM PHYSICIAN, V55, P1761
[7]  
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO
[8]  
2-G
[9]   Bisphosphonates: Mechanism of action and role in clinical practice [J].
Drake, Mathew T. ;
Clarke, Bart L. ;
Khosla, Sundeep .
MAYO CLINIC PROCEEDINGS, 2008, 83 (09) :1032-1045
[10]  
Hattori Seiji, 2004, Gan To Kagaku Ryoho, V31, P271